Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Những quyển sách tương tự

• Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
  Bằng: Sato, Nobuaki, et al.
  Được phát hành: (2018)
• Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
  Bằng: Ueno, Takayuki, et al.
  Được phát hành: (2019)
• Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
  Bằng: Ueno, Takayuki, et al.
  Được phát hành: (2019)
• A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
  Bằng: Ishiguro, Hiroshi, et al.
  Được phát hành: (2020)
• Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
  Bằng: Ueno, Takayuki, et al.
  Được phát hành: (2019)